Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Did Your Heart Skip a Beat? Your Wearable Knows. -- Barrons.com
By Bill Alpert The day is approaching when your wristwatch may send you to the hospital. The first portable electrocardiograph was an 85-pound backpack. Today, a 10-gram patch stuck on your chest ca
Express News | FDA Says Abbott Medical Issues Correction For HeartMate LVAS System Monitor Due To Screen Issues That Could Cause Unintentional Pump Stop
Express News | FDA: Abbott Heartmate Lvas System Monitor Recall Involves Correcting Devices & Does Not Involve Removing Them From Where They Are Used or Sold
Express News | FDA: There Have Been 14 Reported Injuries, No Reports of Death Related to Recall
Express News | FDA: Abbott Medical Issues Correction for Heartmate Lvas System Monitor Due to Screen Issues That May Cause Unintentional Pump Stop
Investors Heavily Search Abbott Laboratories (ABT): Here Is What You Need to Know
Market Whales and Their Recent Bets on ABT Options
Financial giants have made a conspicuous bullish move on Abbott Laboratories. Our analysis of options history for Abbott Laboratories (NYSE:ABT) revealed 8 unusual trades.Delving into the details, we
Unusual Options Activity: CVS, DKNG and Others Attract Market Bets, CVS V/OI Ratio Reaches 137.5
EST Jun 27th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Abbott Hosts Conference Call for Second-Quarter Earnings
Abbott (NYSE: ABT) will announce its second-quarter 2024 financial results on Thursday, July 18, before the market opens. The announcement will be...
Heart Just Skip a Beat? Your Watch Already Knows.
Smart rings and smartwatches are providing consumers with reams of health information. Clinical device makers like DexCom needn't worry.
United States Molecular Diagnostics Market Report 2024-2032 Featuring F Hoffmann-la Roche, Illumina, Hologic, Agilent Technologies, Qiagen, Myriad Genetics, Abbott Laboratories, Danaher, BD & Co
Abbott (ABT) Exceeds Market Returns: Some Facts to Consider
Los Compradores De Ciertos Productos PediaSure En California Pueden Ver Afectados Sus Derechos Por Una Demanda Colectiva
SAN JOSÉ, California, 24 de junio de 2024 /PRNewswire-HISPANIC PR WIRE/ -- ¿De qué se trata la demanda? La demanda sostiene que ciertas declaraciones que Abbott Laboratories ("Abbott") hizo en las
Abbott's (ABT) EPD Expansion Continues Despite FX Headwind
The Zacks Analyst Blog Highlights Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130
TD Cowen analyst Josh Jennings maintains $Abbott Laboratories(ABT.US)$ with a buy rating, and maintains the target price at $130.According to TipRanks data, the analyst has a success rate of 50.8% and
BofA Securities Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
BofA Securities analyst Travis Steed maintains $Abbott Laboratories(ABT.US)$ with a buy rating, and maintains the target price at $133.According to TipRanks data, the analyst has a success rate of 63.
Top Analyst Reports for Abbott, BP & Gilead
Epilepsy Drugs Market, Size, Global Research 2024-2030 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott Laboratories, Alkem Laboratories, Bausch, GSK, Novartis, and Pfizer - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Epilepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis" report has been added to Res